Molecular Cancer-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=590963, encodeId=2a3a590963fc, content=投了一篇综述，不到两个月接收，不知道是好是坏，版面费太高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ep8bWkhQUsZRaEWSVzZypqhCA6SsKStNQJ65SIwWKEFXGJRu0CoDB0GX3IjDXYOGeia1iaZL7W9L6sw/132, createdBy=f6902080981, createdName=fw独家记忆, createdTime=Sat May 16 00:00:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199063, encodeId=dba2119906331, content=偏重的研究方向：circRNA 经验分享：这个杂志里面哪怕有一篇circ的文章是可重复的，我倒立拉屎！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dcf1972913, createdName=填写后不可修改, createdTime=Thu Mar 03 15:15:34 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233172, encodeId=ea6012331e290, content=偏重的研究方向：缺氧;肿瘤;肿瘤转移 经验分享：现在投，基本上要多久啊？有没有好心人介绍下经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=219a5283754, createdName=胸心外科大辣鸡, createdTime=Mon Jul 18 12:01:55 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205868, encodeId=9257120586845, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;靶向治疗 经验分享：最新复旦大咖发表的这篇“Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial”不错。这才是Molecular Cancer现在应该有的水平。这才是20分论文应该有的水平。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Fri Mar 25 15:34:22 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108857, encodeId=d0a5210885eea, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：circRNA 经验分享：2022.3月投的，现在还没审完！请不到审稿人就倒闭算了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53508283991, createdName=ms4000001414066014, createdTime=Thu Jan 05 02:33:12 CST 2023, time=2023-01-05, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1236120, encodeId=d9c8123612051, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肝癌 经验分享：该杂志又被复旦大学附属华山医院预警了，离彻底凉凉已经不远了，不怕死的继续投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ephyuqAymtlDMRohLN2uuz46RrlziauJLvAbftD6K7tvs9bP6BDQuWkA1v323SR995RqtibaobUd3tA/132, createdBy=8a742285606, createdName=121d577cm33(暂无昵称), createdTime=Tue Aug 02 10:46:22 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196797, encodeId=46ae1196e9713, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：molecular cancer 哪怕if37+ 依然上了中信所的预警期刊哈哈哈哈普天同庆喜大普奔大佬们的眼睛是雪亮的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=目标cancer discovery, createdTime=Thu Feb 24 13:18:20 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220577, encodeId=a4b012205e781, content=老师前辈们1 reviewer report received 三个多月了一直没动静可以催一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30135139626, createdName=14672ee2m82暂无昵称, createdTime=Wed May 18 00:01:28 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151627, encodeId=7faf215162e16, content=审稿速度:2.0 偏重的研究方向：circRNA;肿瘤 经验分享：7月20号送审的，今天还没有变化，有没有同样情况的小伙伴。什么时候可以修回呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Mon Aug 07 16:05:21 CST 2023, time=2023-08-07, status=1, ipAttribution=北京)]

2020-05-16 fw独家记忆

投了一篇综述，不到两个月接收，不知道是好是坏，版面费太高了

155 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=590963, encodeId=2a3a590963fc, content=投了一篇综述，不到两个月接收，不知道是好是坏，版面费太高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ep8bWkhQUsZRaEWSVzZypqhCA6SsKStNQJ65SIwWKEFXGJRu0CoDB0GX3IjDXYOGeia1iaZL7W9L6sw/132, createdBy=f6902080981, createdName=fw独家记忆, createdTime=Sat May 16 00:00:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199063, encodeId=dba2119906331, content=偏重的研究方向：circRNA 经验分享：这个杂志里面哪怕有一篇circ的文章是可重复的，我倒立拉屎！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dcf1972913, createdName=填写后不可修改, createdTime=Thu Mar 03 15:15:34 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233172, encodeId=ea6012331e290, content=偏重的研究方向：缺氧;肿瘤;肿瘤转移 经验分享：现在投，基本上要多久啊？有没有好心人介绍下经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=219a5283754, createdName=胸心外科大辣鸡, createdTime=Mon Jul 18 12:01:55 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205868, encodeId=9257120586845, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;靶向治疗 经验分享：最新复旦大咖发表的这篇“Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial”不错。这才是Molecular Cancer现在应该有的水平。这才是20分论文应该有的水平。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Fri Mar 25 15:34:22 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108857, encodeId=d0a5210885eea, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：circRNA 经验分享：2022.3月投的，现在还没审完！请不到审稿人就倒闭算了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53508283991, createdName=ms4000001414066014, createdTime=Thu Jan 05 02:33:12 CST 2023, time=2023-01-05, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1236120, encodeId=d9c8123612051, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肝癌 经验分享：该杂志又被复旦大学附属华山医院预警了，离彻底凉凉已经不远了，不怕死的继续投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ephyuqAymtlDMRohLN2uuz46RrlziauJLvAbftD6K7tvs9bP6BDQuWkA1v323SR995RqtibaobUd3tA/132, createdBy=8a742285606, createdName=121d577cm33(暂无昵称), createdTime=Tue Aug 02 10:46:22 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196797, encodeId=46ae1196e9713, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：molecular cancer 哪怕if37+ 依然上了中信所的预警期刊哈哈哈哈普天同庆喜大普奔大佬们的眼睛是雪亮的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=目标cancer discovery, createdTime=Thu Feb 24 13:18:20 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220577, encodeId=a4b012205e781, content=老师前辈们1 reviewer report received 三个多月了一直没动静可以催一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30135139626, createdName=14672ee2m82暂无昵称, createdTime=Wed May 18 00:01:28 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151627, encodeId=7faf215162e16, content=审稿速度:2.0 偏重的研究方向：circRNA;肿瘤 经验分享：7月20号送审的，今天还没有变化，有没有同样情况的小伙伴。什么时候可以修回呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Mon Aug 07 16:05:21 CST 2023, time=2023-08-07, status=1, ipAttribution=北京)]

2022-03-03 填写后不可修改

偏重的研究方向：circRNA
经验分享：这个杂志里面哪怕有一篇circ的文章是可重复的，我倒立拉屎！

76 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=590963, encodeId=2a3a590963fc, content=投了一篇综述，不到两个月接收，不知道是好是坏，版面费太高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ep8bWkhQUsZRaEWSVzZypqhCA6SsKStNQJ65SIwWKEFXGJRu0CoDB0GX3IjDXYOGeia1iaZL7W9L6sw/132, createdBy=f6902080981, createdName=fw独家记忆, createdTime=Sat May 16 00:00:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199063, encodeId=dba2119906331, content=偏重的研究方向：circRNA 经验分享：这个杂志里面哪怕有一篇circ的文章是可重复的，我倒立拉屎！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dcf1972913, createdName=填写后不可修改, createdTime=Thu Mar 03 15:15:34 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233172, encodeId=ea6012331e290, content=偏重的研究方向：缺氧;肿瘤;肿瘤转移 经验分享：现在投，基本上要多久啊？有没有好心人介绍下经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=219a5283754, createdName=胸心外科大辣鸡, createdTime=Mon Jul 18 12:01:55 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205868, encodeId=9257120586845, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;靶向治疗 经验分享：最新复旦大咖发表的这篇“Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial”不错。这才是Molecular Cancer现在应该有的水平。这才是20分论文应该有的水平。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Fri Mar 25 15:34:22 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108857, encodeId=d0a5210885eea, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：circRNA 经验分享：2022.3月投的，现在还没审完！请不到审稿人就倒闭算了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53508283991, createdName=ms4000001414066014, createdTime=Thu Jan 05 02:33:12 CST 2023, time=2023-01-05, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1236120, encodeId=d9c8123612051, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肝癌 经验分享：该杂志又被复旦大学附属华山医院预警了，离彻底凉凉已经不远了，不怕死的继续投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ephyuqAymtlDMRohLN2uuz46RrlziauJLvAbftD6K7tvs9bP6BDQuWkA1v323SR995RqtibaobUd3tA/132, createdBy=8a742285606, createdName=121d577cm33(暂无昵称), createdTime=Tue Aug 02 10:46:22 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196797, encodeId=46ae1196e9713, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：molecular cancer 哪怕if37+ 依然上了中信所的预警期刊哈哈哈哈普天同庆喜大普奔大佬们的眼睛是雪亮的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=目标cancer discovery, createdTime=Thu Feb 24 13:18:20 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220577, encodeId=a4b012205e781, content=老师前辈们1 reviewer report received 三个多月了一直没动静可以催一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30135139626, createdName=14672ee2m82暂无昵称, createdTime=Wed May 18 00:01:28 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151627, encodeId=7faf215162e16, content=审稿速度:2.0 偏重的研究方向：circRNA;肿瘤 经验分享：7月20号送审的，今天还没有变化，有没有同样情况的小伙伴。什么时候可以修回呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Mon Aug 07 16:05:21 CST 2023, time=2023-08-07, status=1, ipAttribution=北京)]

2022-07-18 胸心外科大辣鸡

偏重的研究方向：缺氧;肿瘤;肿瘤转移
经验分享：现在投，基本上要多久啊？有没有好心人介绍下经验。

55 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=590963, encodeId=2a3a590963fc, content=投了一篇综述，不到两个月接收，不知道是好是坏，版面费太高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ep8bWkhQUsZRaEWSVzZypqhCA6SsKStNQJ65SIwWKEFXGJRu0CoDB0GX3IjDXYOGeia1iaZL7W9L6sw/132, createdBy=f6902080981, createdName=fw独家记忆, createdTime=Sat May 16 00:00:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199063, encodeId=dba2119906331, content=偏重的研究方向：circRNA 经验分享：这个杂志里面哪怕有一篇circ的文章是可重复的，我倒立拉屎！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dcf1972913, createdName=填写后不可修改, createdTime=Thu Mar 03 15:15:34 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233172, encodeId=ea6012331e290, content=偏重的研究方向：缺氧;肿瘤;肿瘤转移 经验分享：现在投，基本上要多久啊？有没有好心人介绍下经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=219a5283754, createdName=胸心外科大辣鸡, createdTime=Mon Jul 18 12:01:55 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205868, encodeId=9257120586845, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;靶向治疗 经验分享：最新复旦大咖发表的这篇“Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial”不错。这才是Molecular Cancer现在应该有的水平。这才是20分论文应该有的水平。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Fri Mar 25 15:34:22 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108857, encodeId=d0a5210885eea, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：circRNA 经验分享：2022.3月投的，现在还没审完！请不到审稿人就倒闭算了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53508283991, createdName=ms4000001414066014, createdTime=Thu Jan 05 02:33:12 CST 2023, time=2023-01-05, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1236120, encodeId=d9c8123612051, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肝癌 经验分享：该杂志又被复旦大学附属华山医院预警了，离彻底凉凉已经不远了，不怕死的继续投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ephyuqAymtlDMRohLN2uuz46RrlziauJLvAbftD6K7tvs9bP6BDQuWkA1v323SR995RqtibaobUd3tA/132, createdBy=8a742285606, createdName=121d577cm33(暂无昵称), createdTime=Tue Aug 02 10:46:22 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196797, encodeId=46ae1196e9713, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：molecular cancer 哪怕if37+ 依然上了中信所的预警期刊哈哈哈哈普天同庆喜大普奔大佬们的眼睛是雪亮的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=目标cancer discovery, createdTime=Thu Feb 24 13:18:20 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220577, encodeId=a4b012205e781, content=老师前辈们1 reviewer report received 三个多月了一直没动静可以催一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30135139626, createdName=14672ee2m82暂无昵称, createdTime=Wed May 18 00:01:28 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151627, encodeId=7faf215162e16, content=审稿速度:2.0 偏重的研究方向：circRNA;肿瘤 经验分享：7月20号送审的，今天还没有变化，有没有同样情况的小伙伴。什么时候可以修回呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Mon Aug 07 16:05:21 CST 2023, time=2023-08-07, status=1, ipAttribution=北京)]

2022-03-25 ms4000001729535049

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤;靶向治疗
经验分享：最新复旦大咖发表的这篇“Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial”不错。这才是Molecular Cancer现在应该有的水平。这才是20分论文应该有的水平。

9 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=590963, encodeId=2a3a590963fc, content=投了一篇综述，不到两个月接收，不知道是好是坏，版面费太高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ep8bWkhQUsZRaEWSVzZypqhCA6SsKStNQJ65SIwWKEFXGJRu0CoDB0GX3IjDXYOGeia1iaZL7W9L6sw/132, createdBy=f6902080981, createdName=fw独家记忆, createdTime=Sat May 16 00:00:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199063, encodeId=dba2119906331, content=偏重的研究方向：circRNA 经验分享：这个杂志里面哪怕有一篇circ的文章是可重复的，我倒立拉屎！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dcf1972913, createdName=填写后不可修改, createdTime=Thu Mar 03 15:15:34 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233172, encodeId=ea6012331e290, content=偏重的研究方向：缺氧;肿瘤;肿瘤转移 经验分享：现在投，基本上要多久啊？有没有好心人介绍下经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=219a5283754, createdName=胸心外科大辣鸡, createdTime=Mon Jul 18 12:01:55 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205868, encodeId=9257120586845, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;靶向治疗 经验分享：最新复旦大咖发表的这篇“Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial”不错。这才是Molecular Cancer现在应该有的水平。这才是20分论文应该有的水平。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Fri Mar 25 15:34:22 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108857, encodeId=d0a5210885eea, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：circRNA 经验分享：2022.3月投的，现在还没审完！请不到审稿人就倒闭算了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53508283991, createdName=ms4000001414066014, createdTime=Thu Jan 05 02:33:12 CST 2023, time=2023-01-05, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1236120, encodeId=d9c8123612051, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肝癌 经验分享：该杂志又被复旦大学附属华山医院预警了，离彻底凉凉已经不远了，不怕死的继续投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ephyuqAymtlDMRohLN2uuz46RrlziauJLvAbftD6K7tvs9bP6BDQuWkA1v323SR995RqtibaobUd3tA/132, createdBy=8a742285606, createdName=121d577cm33(暂无昵称), createdTime=Tue Aug 02 10:46:22 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196797, encodeId=46ae1196e9713, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：molecular cancer 哪怕if37+ 依然上了中信所的预警期刊哈哈哈哈普天同庆喜大普奔大佬们的眼睛是雪亮的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=目标cancer discovery, createdTime=Thu Feb 24 13:18:20 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220577, encodeId=a4b012205e781, content=老师前辈们1 reviewer report received 三个多月了一直没动静可以催一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30135139626, createdName=14672ee2m82暂无昵称, createdTime=Wed May 18 00:01:28 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151627, encodeId=7faf215162e16, content=审稿速度:2.0 偏重的研究方向：circRNA;肿瘤 经验分享：7月20号送审的，今天还没有变化，有没有同样情况的小伙伴。什么时候可以修回呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Mon Aug 07 16:05:21 CST 2023, time=2023-08-07, status=1, ipAttribution=北京)]

2021-07-27 Medicalresearch

under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢

87 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=590963, encodeId=2a3a590963fc, content=投了一篇综述，不到两个月接收，不知道是好是坏，版面费太高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ep8bWkhQUsZRaEWSVzZypqhCA6SsKStNQJ65SIwWKEFXGJRu0CoDB0GX3IjDXYOGeia1iaZL7W9L6sw/132, createdBy=f6902080981, createdName=fw独家记忆, createdTime=Sat May 16 00:00:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199063, encodeId=dba2119906331, content=偏重的研究方向：circRNA 经验分享：这个杂志里面哪怕有一篇circ的文章是可重复的，我倒立拉屎！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dcf1972913, createdName=填写后不可修改, createdTime=Thu Mar 03 15:15:34 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233172, encodeId=ea6012331e290, content=偏重的研究方向：缺氧;肿瘤;肿瘤转移 经验分享：现在投，基本上要多久啊？有没有好心人介绍下经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=219a5283754, createdName=胸心外科大辣鸡, createdTime=Mon Jul 18 12:01:55 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205868, encodeId=9257120586845, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;靶向治疗 经验分享：最新复旦大咖发表的这篇“Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial”不错。这才是Molecular Cancer现在应该有的水平。这才是20分论文应该有的水平。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Fri Mar 25 15:34:22 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108857, encodeId=d0a5210885eea, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：circRNA 经验分享：2022.3月投的，现在还没审完！请不到审稿人就倒闭算了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53508283991, createdName=ms4000001414066014, createdTime=Thu Jan 05 02:33:12 CST 2023, time=2023-01-05, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1236120, encodeId=d9c8123612051, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肝癌 经验分享：该杂志又被复旦大学附属华山医院预警了，离彻底凉凉已经不远了，不怕死的继续投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ephyuqAymtlDMRohLN2uuz46RrlziauJLvAbftD6K7tvs9bP6BDQuWkA1v323SR995RqtibaobUd3tA/132, createdBy=8a742285606, createdName=121d577cm33(暂无昵称), createdTime=Tue Aug 02 10:46:22 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196797, encodeId=46ae1196e9713, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：molecular cancer 哪怕if37+ 依然上了中信所的预警期刊哈哈哈哈普天同庆喜大普奔大佬们的眼睛是雪亮的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=目标cancer discovery, createdTime=Thu Feb 24 13:18:20 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220577, encodeId=a4b012205e781, content=老师前辈们1 reviewer report received 三个多月了一直没动静可以催一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30135139626, createdName=14672ee2m82暂无昵称, createdTime=Wed May 18 00:01:28 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151627, encodeId=7faf215162e16, content=审稿速度:2.0 偏重的研究方向：circRNA;肿瘤 经验分享：7月20号送审的，今天还没有变化，有没有同样情况的小伙伴。什么时候可以修回呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Mon Aug 07 16:05:21 CST 2023, time=2023-08-07, status=1, ipAttribution=北京)]

2023-01-05 ms4000001414066014 来自河南省

审稿速度:12.0 | 投稿命中率:25.0
偏重的研究方向：circRNA
经验分享：2022.3月投的，现在还没审完！请不到审稿人就倒闭算了

89 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=590963, encodeId=2a3a590963fc, content=投了一篇综述，不到两个月接收，不知道是好是坏，版面费太高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ep8bWkhQUsZRaEWSVzZypqhCA6SsKStNQJ65SIwWKEFXGJRu0CoDB0GX3IjDXYOGeia1iaZL7W9L6sw/132, createdBy=f6902080981, createdName=fw独家记忆, createdTime=Sat May 16 00:00:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199063, encodeId=dba2119906331, content=偏重的研究方向：circRNA 经验分享：这个杂志里面哪怕有一篇circ的文章是可重复的，我倒立拉屎！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dcf1972913, createdName=填写后不可修改, createdTime=Thu Mar 03 15:15:34 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233172, encodeId=ea6012331e290, content=偏重的研究方向：缺氧;肿瘤;肿瘤转移 经验分享：现在投，基本上要多久啊？有没有好心人介绍下经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=219a5283754, createdName=胸心外科大辣鸡, createdTime=Mon Jul 18 12:01:55 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205868, encodeId=9257120586845, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;靶向治疗 经验分享：最新复旦大咖发表的这篇“Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial”不错。这才是Molecular Cancer现在应该有的水平。这才是20分论文应该有的水平。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Fri Mar 25 15:34:22 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108857, encodeId=d0a5210885eea, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：circRNA 经验分享：2022.3月投的，现在还没审完！请不到审稿人就倒闭算了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53508283991, createdName=ms4000001414066014, createdTime=Thu Jan 05 02:33:12 CST 2023, time=2023-01-05, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1236120, encodeId=d9c8123612051, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肝癌 经验分享：该杂志又被复旦大学附属华山医院预警了，离彻底凉凉已经不远了，不怕死的继续投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ephyuqAymtlDMRohLN2uuz46RrlziauJLvAbftD6K7tvs9bP6BDQuWkA1v323SR995RqtibaobUd3tA/132, createdBy=8a742285606, createdName=121d577cm33(暂无昵称), createdTime=Tue Aug 02 10:46:22 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196797, encodeId=46ae1196e9713, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：molecular cancer 哪怕if37+ 依然上了中信所的预警期刊哈哈哈哈普天同庆喜大普奔大佬们的眼睛是雪亮的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=目标cancer discovery, createdTime=Thu Feb 24 13:18:20 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220577, encodeId=a4b012205e781, content=老师前辈们1 reviewer report received 三个多月了一直没动静可以催一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30135139626, createdName=14672ee2m82暂无昵称, createdTime=Wed May 18 00:01:28 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151627, encodeId=7faf215162e16, content=审稿速度:2.0 偏重的研究方向：circRNA;肿瘤 经验分享：7月20号送审的，今天还没有变化，有没有同样情况的小伙伴。什么时候可以修回呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Mon Aug 07 16:05:21 CST 2023, time=2023-08-07, status=1, ipAttribution=北京)]

2022-08-02 121d577cm33(暂无昵称)

审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向：肝癌
经验分享：该杂志又被复旦大学附属华山医院预警了，离彻底凉凉已经不远了，不怕死的继续投！

165 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=590963, encodeId=2a3a590963fc, content=投了一篇综述，不到两个月接收，不知道是好是坏，版面费太高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ep8bWkhQUsZRaEWSVzZypqhCA6SsKStNQJ65SIwWKEFXGJRu0CoDB0GX3IjDXYOGeia1iaZL7W9L6sw/132, createdBy=f6902080981, createdName=fw独家记忆, createdTime=Sat May 16 00:00:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199063, encodeId=dba2119906331, content=偏重的研究方向：circRNA 经验分享：这个杂志里面哪怕有一篇circ的文章是可重复的，我倒立拉屎！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dcf1972913, createdName=填写后不可修改, createdTime=Thu Mar 03 15:15:34 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233172, encodeId=ea6012331e290, content=偏重的研究方向：缺氧;肿瘤;肿瘤转移 经验分享：现在投，基本上要多久啊？有没有好心人介绍下经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=219a5283754, createdName=胸心外科大辣鸡, createdTime=Mon Jul 18 12:01:55 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205868, encodeId=9257120586845, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;靶向治疗 经验分享：最新复旦大咖发表的这篇“Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial”不错。这才是Molecular Cancer现在应该有的水平。这才是20分论文应该有的水平。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Fri Mar 25 15:34:22 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108857, encodeId=d0a5210885eea, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：circRNA 经验分享：2022.3月投的，现在还没审完！请不到审稿人就倒闭算了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53508283991, createdName=ms4000001414066014, createdTime=Thu Jan 05 02:33:12 CST 2023, time=2023-01-05, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1236120, encodeId=d9c8123612051, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肝癌 经验分享：该杂志又被复旦大学附属华山医院预警了，离彻底凉凉已经不远了，不怕死的继续投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ephyuqAymtlDMRohLN2uuz46RrlziauJLvAbftD6K7tvs9bP6BDQuWkA1v323SR995RqtibaobUd3tA/132, createdBy=8a742285606, createdName=121d577cm33(暂无昵称), createdTime=Tue Aug 02 10:46:22 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196797, encodeId=46ae1196e9713, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：molecular cancer 哪怕if37+ 依然上了中信所的预警期刊哈哈哈哈普天同庆喜大普奔大佬们的眼睛是雪亮的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=目标cancer discovery, createdTime=Thu Feb 24 13:18:20 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220577, encodeId=a4b012205e781, content=老师前辈们1 reviewer report received 三个多月了一直没动静可以催一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30135139626, createdName=14672ee2m82暂无昵称, createdTime=Wed May 18 00:01:28 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151627, encodeId=7faf215162e16, content=审稿速度:2.0 偏重的研究方向：circRNA;肿瘤 经验分享：7月20号送审的，今天还没有变化，有没有同样情况的小伙伴。什么时候可以修回呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Mon Aug 07 16:05:21 CST 2023, time=2023-08-07, status=1, ipAttribution=北京)]

2022-02-24 目标cancer discovery

审稿速度:1.0 | 投稿命中率:95.0
偏重的研究方向：肿瘤
经验分享：molecular cancer 哪怕if37+ 依然上了中信所的预警期刊哈哈哈哈普天同庆喜大普奔大佬们的眼睛是雪亮的

69 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=590963, encodeId=2a3a590963fc, content=投了一篇综述，不到两个月接收，不知道是好是坏，版面费太高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ep8bWkhQUsZRaEWSVzZypqhCA6SsKStNQJ65SIwWKEFXGJRu0CoDB0GX3IjDXYOGeia1iaZL7W9L6sw/132, createdBy=f6902080981, createdName=fw独家记忆, createdTime=Sat May 16 00:00:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199063, encodeId=dba2119906331, content=偏重的研究方向：circRNA 经验分享：这个杂志里面哪怕有一篇circ的文章是可重复的，我倒立拉屎！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dcf1972913, createdName=填写后不可修改, createdTime=Thu Mar 03 15:15:34 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233172, encodeId=ea6012331e290, content=偏重的研究方向：缺氧;肿瘤;肿瘤转移 经验分享：现在投，基本上要多久啊？有没有好心人介绍下经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=219a5283754, createdName=胸心外科大辣鸡, createdTime=Mon Jul 18 12:01:55 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205868, encodeId=9257120586845, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;靶向治疗 经验分享：最新复旦大咖发表的这篇“Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial”不错。这才是Molecular Cancer现在应该有的水平。这才是20分论文应该有的水平。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Fri Mar 25 15:34:22 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108857, encodeId=d0a5210885eea, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：circRNA 经验分享：2022.3月投的，现在还没审完！请不到审稿人就倒闭算了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53508283991, createdName=ms4000001414066014, createdTime=Thu Jan 05 02:33:12 CST 2023, time=2023-01-05, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1236120, encodeId=d9c8123612051, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肝癌 经验分享：该杂志又被复旦大学附属华山医院预警了，离彻底凉凉已经不远了，不怕死的继续投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ephyuqAymtlDMRohLN2uuz46RrlziauJLvAbftD6K7tvs9bP6BDQuWkA1v323SR995RqtibaobUd3tA/132, createdBy=8a742285606, createdName=121d577cm33(暂无昵称), createdTime=Tue Aug 02 10:46:22 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196797, encodeId=46ae1196e9713, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：molecular cancer 哪怕if37+ 依然上了中信所的预警期刊哈哈哈哈普天同庆喜大普奔大佬们的眼睛是雪亮的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=目标cancer discovery, createdTime=Thu Feb 24 13:18:20 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220577, encodeId=a4b012205e781, content=老师前辈们1 reviewer report received 三个多月了一直没动静可以催一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30135139626, createdName=14672ee2m82暂无昵称, createdTime=Wed May 18 00:01:28 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151627, encodeId=7faf215162e16, content=审稿速度:2.0 偏重的研究方向：circRNA;肿瘤 经验分享：7月20号送审的，今天还没有变化，有没有同样情况的小伙伴。什么时候可以修回呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Mon Aug 07 16:05:21 CST 2023, time=2023-08-07, status=1, ipAttribution=北京)]

2022-05-18 14672ee2m82暂无昵称

老师前辈们1 reviewer report received 三个多月了一直没动静可以催一下吗

89 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=590963, encodeId=2a3a590963fc, content=投了一篇综述，不到两个月接收，不知道是好是坏，版面费太高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ep8bWkhQUsZRaEWSVzZypqhCA6SsKStNQJ65SIwWKEFXGJRu0CoDB0GX3IjDXYOGeia1iaZL7W9L6sw/132, createdBy=f6902080981, createdName=fw独家记忆, createdTime=Sat May 16 00:00:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199063, encodeId=dba2119906331, content=偏重的研究方向：circRNA 经验分享：这个杂志里面哪怕有一篇circ的文章是可重复的，我倒立拉屎！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dcf1972913, createdName=填写后不可修改, createdTime=Thu Mar 03 15:15:34 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1233172, encodeId=ea6012331e290, content=偏重的研究方向：缺氧;肿瘤;肿瘤转移 经验分享：现在投，基本上要多久啊？有没有好心人介绍下经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=219a5283754, createdName=胸心外科大辣鸡, createdTime=Mon Jul 18 12:01:55 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205868, encodeId=9257120586845, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;靶向治疗 经验分享：最新复旦大咖发表的这篇“Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial”不错。这才是Molecular Cancer现在应该有的水平。这才是20分论文应该有的水平。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a3ed5633363, createdName=ms4000001729535049, createdTime=Fri Mar 25 15:34:22 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003000, encodeId=82231003000b1, content=under review21天，又回到editor assigned状态，有同志有类似情况吗？求解，万分感谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dfaa5456833, createdName=Medicalresearch, createdTime=Tue Jul 27 14:14:25 CST 2021, time=2021-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2108857, encodeId=d0a5210885eea, content=审稿速度:12.0 | 投稿命中率:25.0 偏重的研究方向：circRNA 经验分享：2022.3月投的，现在还没审完！请不到审稿人就倒闭算了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53508283991, createdName=ms4000001414066014, createdTime=Thu Jan 05 02:33:12 CST 2023, time=2023-01-05, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1236120, encodeId=d9c8123612051, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肝癌 经验分享：该杂志又被复旦大学附属华山医院预警了，离彻底凉凉已经不远了，不怕死的继续投！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ephyuqAymtlDMRohLN2uuz46RrlziauJLvAbftD6K7tvs9bP6BDQuWkA1v323SR995RqtibaobUd3tA/132, createdBy=8a742285606, createdName=121d577cm33(暂无昵称), createdTime=Tue Aug 02 10:46:22 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196797, encodeId=46ae1196e9713, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：molecular cancer 哪怕if37+ 依然上了中信所的预警期刊哈哈哈哈普天同庆喜大普奔大佬们的眼睛是雪亮的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=目标cancer discovery, createdTime=Thu Feb 24 13:18:20 CST 2022, time=2022-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220577, encodeId=a4b012205e781, content=老师前辈们1 reviewer report received 三个多月了一直没动静可以催一下吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30135139626, createdName=14672ee2m82暂无昵称, createdTime=Wed May 18 00:01:28 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151627, encodeId=7faf215162e16, content=审稿速度:2.0 偏重的研究方向：circRNA;肿瘤 经验分享：7月20号送审的，今天还没有变化，有没有同样情况的小伙伴。什么时候可以修回呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47dd6406460, createdName=ms4000001583479348, createdTime=Mon Aug 07 16:05:21 CST 2023, time=2023-08-07, status=1, ipAttribution=北京)]

2023-08-07 ms4000001583479348 来自北京

审稿速度:2.0
偏重的研究方向：circRNA;肿瘤
经验分享：7月20号送审的，今天还没有变化，有没有同样情况的小伙伴。什么时候可以修回呀

53 7

展开7条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务